Safety and tolerability of dapsone for the treatment of patients with drug-resistant, partial-onset seizures: an open-label trial
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Mario Lo´pez-Go´mez • Teresa Corona • Araceli Diaz-Ruiz • Camilo R´os
- چاپ و سال / کشور: 2011
Description
Dapsone has shown anti-convulsive properties in animal models of epilepsy. In the present study, we tested the safety and tolerability of dapsone as adjunctive therapy in adult patients with drug-resistant partial-onset seizures. Twenty-two adult patients with drug-resistant partial-onset seizures were included. After a 3-month baseline period, patients received dapsone 100 mg per day, for a 3-month evaluation period. Plasma concentrations of anti-epileptic drugs (AEDs) did not significantly change during the study. No alteration of mean clinical laboratory values was observed. The reported adverse events were: mild methemoglobinemia (50%), headache (31.8%), paleness (27.3%) and somnolence (4.5%).Sixteen of 22 patients reduced their seizure frequency in more than 50% as a result of dapsone treatment. Three subjects remained seizure- free during the entire dapsone treatment period. This open-label study of adjunctive dapsone therapy at 100 mg/ day suggests that dapsone is safe, and well-tolerated in adults with drug-resistant partial-onset seizures.
Neurol Sci DOI 10.1007/s10072-011-0612-6 Received: 14 September 2010 / Accepted: 28 April 2011
